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 New Ways of Thinking about Proteinuria 
and Progression of Renal Damage 
 Y.S. Zhou    A.N. Turner 
 MRC Centre for Inflammation, University of Edinburgh,  Edinburgh , UK 
 The ‘Podocyte-Progression hypothesis’  [3–5] postu-
lates that continuing, progressive podocyte damage or 
loss is central to the progression of proteinuric renal dis-
eases. This mechanism of progression might also be ex-
tended to diseases in which podocyte damage is not the 
primary problem, but in which proteinuria occurs later, 
possibly in hyperfiltering glomeruli, for example.
 If we believe this, we might expect nephroprotective, 
proteinuria-lowering treatments to act not via haemody-
namic or anti-fibrotic effects, but on podocytes them-
selves. Evidence to support this hypothesis is now strong. 
It turns out that podocytes are dynamic, active, mobile 
cells that are studded with scores of receptor types en-
abling them to respond to external mediators. The slit 
diaphragm is not a static barrier to protein; it is suscep-
tible to a wide range of external influences both chemical 
and mechanical.
 Five years ago came the first suggestion that one of our 
key immunosuppressive agents, corticosteroids – the 
mainstay of therapy for minimal change nephrotic syn-
drome – might have direct structure-protective effects on 
podocytes  [6] . That has recently been added to by the ob-
servation that the immunosuppressive calcineurin inhib-
itor tacrolimus has similar direct effects  [7, 8] . Both of 
these drugs had previously been assumed to be acting 
through the immune system, though that fitted poorly 
with the observation that calcineurin inhibitors seemed 
to reduce proteinuria regardless of the cause. The evi-
 Reducing proteinuria is often a target of treatment 
 because of the close correlation between improvement
of proteinuria and better renal outcomes in human stud-
ies involving angiotensin-converting enzyme inhibitors 
(ACEI) and angiotensin receptor blockers (ARB).
 Conventional explanations for the protective effects of 
ACEI and ARB centre on their haemodynamic effects, 
suggesting that reducing glomerular filtration pressure is 
the key to their protective action. The fact that blood 
pressure reduction by any means protects renal function 
in proteinuric renal disease (the Modification of Diet in 
Renal Disease Study) suggests that this can explain at 
least some of the effect. Others have added that ACEI/
ARB may also modulate the toxicity of filtered proteins 
by effects on non-glomerular cells  [1] . The close correla-
tion between long-term outcomes and proteinuria has 
triggered a large body of work documenting potential 
mechanisms by which excessive filtered protein may 
damage renal tubular cells and promote interstitial fibro-
sis  [2] .
 An alternative hypothesis is emerging from the mush-
rooming field of podocyte biology. Podocytes have been 
show to play a central role in many or most proteinuric 
diseases – almost all of the inherited causes of severe pro-
teinuria involve podocyte genes and many acquired pro-
teinuric diseases can point to podocyte malfunction as 
well. Proteinuria is known to be a consequence of podo-
cyte malfunction or damage.
 Published online: May 21, 2010 
 Neil Turner 
 Renal and Autoimmunity Group 
 MRC Centre for Inflammation, University of Edinburgh 
 Hugh Robson Building, 14 George Square, Edinburgh EH8 9XD (UK) 
 Tel. +44 131 651 1795, Fax +44 131 651 1848, E-Mail neil.turner   @   ed.ac.uk 
 © 2010 S. Karger AG, Basel
1660–2129/10/1161–0001$26.00/0 
 Accessible online at:
www.karger.com/nee 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ity
 o
f E
di
nb
ur
gh
   
   
   
   
   
   
   
   
   
   
  
12
9.
21
5.
4.
1 
- 6
/1
9/
20
13
 1
:3
2:
32
 A
M
 Zhou/Turner
 
Nephron Exp Nephrol 2010;116:e1–e2e2
dence that minimal change nephropathy is an immune-
mediated condition now looks seriously weakened. It is 
fascinating that drugs acting on the immune system can 
have such effects on podocytes and this must point to 
shared signalling pathways.
 It is logical to ask next whether other drugs that appear 
to reduce proteinuria, or maintain remissions in nephrot-
ic syndrome, could have direct actions on podocytes. In 
this issue, Takeuchi et al.  [9] set out to investigate the im-
idazole nucleoside mizoribine, which is an inhibitor of 
purine nucleotide synthesis that is apparently commonly 
used as an immunosuppressant in Japan.
 The chosen model was puromycin aminonucleoside 
(PAN) nephropathy in rats. PAN is believed to act pri-
marily as a podocyte toxin in this model, causing protein-
uria and podocyte injury. Mizoribine acted to protect 
podocytes in vitro against loss of actin structure and cell 
death induced by puromycin and in the in vivo model, it 
reduced proteinuria and preserved nephrin distribution 
pattern at 9 days. Unfortunately, this is the limit of the in 
vivo data but a protective effect has been described previ-
ously by another group. Some observations on potential 
mechanisms are presented and it is interesting that the 
investigators found that there was no evidence in their
in vitro system to support a mechanism involving in-
hibition of inosine 5  -monophosphate dehydrogenase, 
thought to be the main immunosuppressive action of the 
drug.
 Interestingly or surprisingly, in this same in vitro sys-
tem the investigators found no protection from mycophe-
nolate mofetil, which is quite extensively used to main-
tain remission in minimal change disease.
 It is only fair to point out that the published random-
ized controlled trial evidence for the efficacy of mizorib-
ine in nephrotic syndrome is rather limited, and a Co-
chrane review  [10] regarded it as inconclusive. However, 
the evidence for mycophenolate mofetil is not solid either. 
Further studies of potential actions of nephroprotective 
drugs on podocytes are to be looked forward to.
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